Cambridge, Mass.-based Biogen will cut about 1,000 jobs as it plans to save $700 million by 2025, the company said July 25.
About 7,000 people work at Biogen worldwide, according to its LinkedIn page, meaning it plans to reduce its workforce by more than than 10 percent.
The biotech recently secured full approval for Leqembi, an Alzheimer's drug label it shares with Japan-based Eisai. It plans to launch the drug by the end of 2023.
The company has not submitted a WARN notice in Massachusetts, according to the state's records, which were last updated July 21.